BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD

BI Asset Management Fondsmaeglerselskab A S grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 35.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 538,969 shares of the biopharmaceutical company’s stock after buying an additional 140,158 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Gilead Sciences were worth $59,755,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Activest Wealth Management lifted its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC boosted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the 2nd quarter valued at about $30,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 2.3%

Shares of NASDAQ:GILD opened at $120.40 on Friday. The firm has a market capitalization of $149.38 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.68 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The firm has a fifty day moving average of $121.89 and a 200 day moving average of $115.71.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Activity

In other news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 135,757 shares of company stock valued at $16,616,127. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GILD shares. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Needham & Company LLC raised their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Truist Financial assumed coverage on Gilead Sciences in a research note on Monday, November 24th. They set a “buy” rating and a $140.00 price objective for the company. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $131.13.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.